It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EMITF’s FA Score shows that 1 FA rating(s) are green whileNUWE’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EMITF’s TA Score shows that 0 TA indicator(s) are bullish while NUWE’s TA Score has 4 bullish TA indicator(s).
EMITF (@Financial Conglomerates) experienced а 0.00% price change this week, while NUWE (@Medical/Nursing Services) price change was -6.84% for the same time period.
The average weekly price growth across all stocks in the @Financial Conglomerates industry was +1.72%. For the same industry, the average monthly price growth was +1.99%, and the average quarterly price growth was +66.20%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.17%. For the same industry, the average monthly price growth was +0.53%, and the average quarterly price growth was +12.11%.
Financial conglomerates usually encompass a wide range of financial services including (not necessarily limited to) investment banking, insurance, capital raising/underwriting, trading of financial securities, investment advisory services, wealth management of high net-worth individuals, and retail banking. Think Citigroup, American Express Company, ING Group.
@Medical/Nursing Services (-0.17% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| EMITF | NUWE | EMITF / NUWE | |
| Capitalization | 16.2M | 2.21M | 732% |
| EBITDA | 7.74M | -3.84M | -202% |
| Gain YTD | -96.600 | -94.745 | 102% |
| P/E Ratio | N/A | 0.01 | - |
| Revenue | 0 | 8.32M | - |
| Total Cash | 42.1M | 4.45M | 946% |
| Total Debt | N/A | 438K | - |
EMITF | NUWE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 99 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 90 | 100 | |
PRICE GROWTH RATING 1..100 | 99 | 65 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EMITF's Valuation (15) in the Real Estate Development industry is in the same range as NUWE (27) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
EMITF's Profit vs Risk Rating (100) in the Real Estate Development industry is in the same range as NUWE (100) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
EMITF's SMR Rating (90) in the Real Estate Development industry is in the same range as NUWE (100) in the Medical Specialties industry. This means that EMITF’s stock grew similarly to NUWE’s over the last 12 months.
NUWE's Price Growth Rating (65) in the Medical Specialties industry is somewhat better than the same rating for EMITF (99) in the Real Estate Development industry. This means that NUWE’s stock grew somewhat faster than EMITF’s over the last 12 months.
NUWE's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as EMITF (100) in the Real Estate Development industry. This means that NUWE’s stock grew similarly to EMITF’s over the last 12 months.
| EMITF | NUWE | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 84% |
| Stochastic ODDS (%) | N/A | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 50% | 2 days ago 89% |
| MACD ODDS (%) | 2 days ago 55% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 37% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 41% | 2 days ago 90% |
| Advances ODDS (%) | N/A | 9 days ago 79% |
| Declines ODDS (%) | N/A | 22 days ago 90% |
| BollingerBands ODDS (%) | N/A | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 44% | 2 days ago 90% |
A.I.dvisor tells us that EMITF and AVHHL have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EMITF and AVHHL's prices will move in lockstep.
| Ticker / NAME | Correlation To EMITF | 1D Price Change % | ||
|---|---|---|---|---|
| EMITF | 100% | N/A | ||
| AVHHL - EMITF | 26% Poorly correlated | N/A | ||
| KLYG - EMITF | 24% Poorly correlated | N/A | ||
| ASAPF - EMITF | 24% Poorly correlated | -2.20% | ||
| IQV - EMITF | 23% Poorly correlated | +1.37% | ||
| PHG - EMITF | 15% Poorly correlated | +0.04% | ||
More | ||||
A.I.dvisor tells us that NUWE and VTAK have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NUWE and VTAK's prices will move in lockstep.
| Ticker / NAME | Correlation To NUWE | 1D Price Change % | ||
|---|---|---|---|---|
| NUWE | 100% | -13.73% | ||
| VTAK - NUWE | 30% Poorly correlated | -9.87% | ||
| VAPO - NUWE | 30% Poorly correlated | N/A | ||
| CORBF - NUWE | 24% Poorly correlated | +0.01% | ||
| PRE - NUWE | 24% Poorly correlated | +8.18% | ||
| BNR - NUWE | 23% Poorly correlated | +0.12% | ||
More | ||||